AACR 2026 - Returning to AACR with New Solutions for Oncology Research

From April 17 to 22, 2026, the Annual Meeting of the American Association for Cancer Research (AACR) was held at the San Diego Convention Center in California, USA. As one of the most influential and authoritative global conferences in oncology research, the meeting brought together more than 22,000 professionals from over 140 countries and regions.

Biolight Biotechnology (hereinafter referred to as BLT) returned to AACR for the second time, engaging in in-depth scientific exchange with leading researchers worldwide and exploring emerging applications in life sciences and oncology research.

New Product Launch: Expanding Our Integrated Laboratory Instrument Portfolio

During the six-day exhibition, the BLT booth attracted significant attention from researchers across academia and industry. The company showcased its newly launched InnoElectro360 Multifunctional Electrophoresis Workstation, further strengthening its portfolio of basic laboratory instruments and expanding its integrated solutions for research workflows.

Designed for routine laboratory applications, InnoElectro360 supports a wide range of standard electrophoresis experiments. With its practical and integrated design, it received strong interest from international researchers and demonstrated robust adaptability across diverse experimental settings.

Advancing Core Technologies: The AniView Series Small Animal In Vivo Imaging System

At AACR 2026, BLT prominently presented its flagship AniView series small animal in vivo imaging system, highlighting the company’s continued innovation and technical expertise in preclinical imaging.

The AniView series features high-sensitivity detection, multimodal imaging capabilities, and intelligent data analysis, enabling comprehensive support for oncology research models, including subcutaneous tumor models as well as orthotopic and metastatic tumor models. It provides reliable visualization and quantitative analysis for a wide range of preclinical cancer studies.

From First Appearance to Continued Progress: Advancing Global Oncology Research with Biolight Innovation

From its initial participation to its second appearance at AACR, BLT continues to demonstrate steady growth in global scientific engagement and technological development. Building on extensive experience in in vivo imaging, the company integrates advanced instrumentation with application-oriented technical support to deliver comprehensive imaging solutions tailored to evolving needs in cancer research.

To date, BLT in vivo imaging systems have been deployed in more than 350 laboratories worldwide, spanning over 10 countries and regions across Europe, North America, and Asia. These systems have contributed to more than 700 SCI-indexed publications, with a cumulative impact factor exceeding 7,000.

Committed to independent innovation, BLT continues to refine its technologies and expand its product portfolio. Through participation in leading international scientific conferences, the company strengthens global collaboration and enhances recognition within the scientific community.

Looking ahead, Biolight will continue to deliver high-quality, independently developed scientific instruments and integrated imaging solutions, supporting advancements in cancer research and life sciences worldwide.